The cell therapy market size has grown rapidly in recent years. It will grow from $12.58 billion in 2023 to $14.72 billion in 2024 at a compound annual growth rate (CAGR) of 17.0%. The growth observed in the historical period can be ascribed to early research and discoveries, regulatory milestones, clinical trials and studies, early adopters and pioneering companies, as well as market acceptance and perception.
The cell therapy market size is expected to see rapid growth in the next few years. It will grow to $25.86 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%. The growth anticipated in the forecast period can be ascribed to ethical and societal considerations, trends in investment and funding, consumer/patient demand, healthcare infrastructure, and rapid innovation cycles. Key trends during the forecast period include personalized medicine, the emergence of targeted treatments, advancements in gene editing technologies, the expansion of stem cell research, breakthroughs in immunotherapy, and manipulation of the microenvironment.
The expansion of the cell therapy market has been facilitated by the increasing prevalence of chronic diseases. Chronic diseases, as defined by the US Centers for Disease Control and Prevention (CDC), persist for one year or more, necessitate medical attention, limit daily activities, or exhibit both characteristics. Conditions such as heart disease, cancer, diabetes, and Parkinson's disease fall under this category. Stem cells offer benefits to patients grappling with spinal cord injuries, type 1 diabetes, Parkinson's disease, heart disease, cancer, and osteoarthritis. The CDC reported in 2021 that poor nutrition and lack of physical activity have resulted in six out of ten adults in the USA suffering from chronic diseases, with four out of ten experiencing two or more such conditions. Moreover, the International Diabetes Federation projected that by 2030, approximately 643 million people worldwide will have diabetes. The prevalence of chronic diseases, such as Parkinson's, further contributes to the demand for cell therapies, fostering growth in the cell therapy market.
Anticipated growth in investments is poised to drive the expansion of the cell therapy market. Investment in cell therapy involves allocating financial resources to support research, development, manufacturing, and commercialization of cell-based therapies. This financial backing aids the advancement of new cell therapy products and technologies, as well as the execution of clinical trials to assess their efficacy. Notably, a report by Cell & Gene revealed a remarkable surge in cell therapy investment, soaring from $362 million in 2020 to nearly $68 billion in 2021. This substantial increase in investment is a key driver for the growth of the cell therapy market.
Despite the growing demand for cell therapies, the high cost associated with these treatments poses a significant hindrance to the cell therapy industry. While cell therapies have gained popularity, their expense remains a considerable barrier. Basic joint injections can cost around $1,000, while more specialized procedures can reach up to $100,000, depending on the condition. In the United States, the average cost of stem cell therapy in 2020 was estimated to range between $4,000 and $8,000 per patient. This financial barrier impedes the broader growth of the cell therapy market.
Key players in the cell therapy market are strategically engaging in partnerships and collaborations to expand their product portfolios and geographic reach. Takeda, a Japan-based pharmaceutical company, acquired GammaDelta Therapeutics, a US-based cell therapy company, in October 2021 to accelerate the development of allogeneic T cell therapies for solid tumors. Additionally, in June 2021, Charles River Laboratories, a US-based pharmaceutical company, acquired Vigene Biosciences Inc., a US-based biotech company, to enhance gene therapy capabilities and establish an end-to-end gene therapy solution in the US. This strategic approach is aimed at fostering long-term revenue and earnings growth potential.
Major companies in the cell therapy market are opting for strategic partnerships to deliver innovative and effective therapies. Genentech Inc., a US biotechnology corporation, partnered with Arsenal Biosciences, Inc., a US-based programmable cell therapy company, in September 2022. The collaboration aims to expedite the development of next-generation cell therapy products, particularly for solid tumors, potentially revolutionizing cancer treatment. This commitment to innovation and collaboration reflects a shared goal of advancing new and effective treatments for cancer patients.
In October 2021, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, acquired GammaDelta Therapeutics Limited for $100 million. This acquisition enabled Takeda to gain access to early-stage cell therapy programs and GammaDelta's allogeneic variable delta 1 (V1) gamma-delta T cell therapy platforms, encompassing both blood-derived and tissue-derived platforms. GammaDelta Therapeutics Limited, based in the UK, specializes in researching and developing T-cell therapy and immunotherapy for cancer treatment.
Major companies operating in the cell therapy market report are Celgene Corporation, JCR Pharmaceuticals Co. Ltd., Baxter Healthcare Corporation, Nipro Corporation, Stempeutics Research Pvt. Ltd., Osiris Therapeutics Inc., Vericel Corporation, AlloSource, Anterogen Co. Ltd., Arteriocyte Medical Systems Inc., MediPost Co. Ltd., Pharmicell Co. Ltd., Corestem Inc., Stemedica Cell Technologies Inc., Adaptimmune Therapeutics PLC, Mesoblast Ltd., Cell Medica Ltd., Cellerant Therapeutics Inc., Kolon TissueGene Inc., Tego Science Inc., Athersys Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Forticell Bioscience Inc., Bone Therapeutics, Holostem Terapie Avanzate S.r.l, Fibrocell Science Inc., AlloCure Inc., TiGenix NV, Cells for Cells, AVROBIO Inc., Cellular Biomedicine Group Inc., Thermo Fisher Scientific Inc., Merck Co. & KGaA, Charles River Laboratories International Inc., Lonza Group Ltd., Catalent Inc. North America was the largest region in the cell therapy market in 2023. The regions covered in the cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The primary techniques employed in cell therapy include stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell treatment, also recognized as regenerative medicine, utilizes stem cells or their derivatives to stimulate the healing response in diseased, defective, or injured tissues. Allogeneic therapies and autologous therapies are the two main types of therapies used in various applications such as oncology, cardiovascular disease (CVD), orthopedics, wound healing, and more.
The cell therapy market research report is one of a series of new reports that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cell therapy market size is expected to see rapid growth in the next few years. It will grow to $25.86 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%. The growth anticipated in the forecast period can be ascribed to ethical and societal considerations, trends in investment and funding, consumer/patient demand, healthcare infrastructure, and rapid innovation cycles. Key trends during the forecast period include personalized medicine, the emergence of targeted treatments, advancements in gene editing technologies, the expansion of stem cell research, breakthroughs in immunotherapy, and manipulation of the microenvironment.
The expansion of the cell therapy market has been facilitated by the increasing prevalence of chronic diseases. Chronic diseases, as defined by the US Centers for Disease Control and Prevention (CDC), persist for one year or more, necessitate medical attention, limit daily activities, or exhibit both characteristics. Conditions such as heart disease, cancer, diabetes, and Parkinson's disease fall under this category. Stem cells offer benefits to patients grappling with spinal cord injuries, type 1 diabetes, Parkinson's disease, heart disease, cancer, and osteoarthritis. The CDC reported in 2021 that poor nutrition and lack of physical activity have resulted in six out of ten adults in the USA suffering from chronic diseases, with four out of ten experiencing two or more such conditions. Moreover, the International Diabetes Federation projected that by 2030, approximately 643 million people worldwide will have diabetes. The prevalence of chronic diseases, such as Parkinson's, further contributes to the demand for cell therapies, fostering growth in the cell therapy market.
Anticipated growth in investments is poised to drive the expansion of the cell therapy market. Investment in cell therapy involves allocating financial resources to support research, development, manufacturing, and commercialization of cell-based therapies. This financial backing aids the advancement of new cell therapy products and technologies, as well as the execution of clinical trials to assess their efficacy. Notably, a report by Cell & Gene revealed a remarkable surge in cell therapy investment, soaring from $362 million in 2020 to nearly $68 billion in 2021. This substantial increase in investment is a key driver for the growth of the cell therapy market.
Despite the growing demand for cell therapies, the high cost associated with these treatments poses a significant hindrance to the cell therapy industry. While cell therapies have gained popularity, their expense remains a considerable barrier. Basic joint injections can cost around $1,000, while more specialized procedures can reach up to $100,000, depending on the condition. In the United States, the average cost of stem cell therapy in 2020 was estimated to range between $4,000 and $8,000 per patient. This financial barrier impedes the broader growth of the cell therapy market.
Key players in the cell therapy market are strategically engaging in partnerships and collaborations to expand their product portfolios and geographic reach. Takeda, a Japan-based pharmaceutical company, acquired GammaDelta Therapeutics, a US-based cell therapy company, in October 2021 to accelerate the development of allogeneic T cell therapies for solid tumors. Additionally, in June 2021, Charles River Laboratories, a US-based pharmaceutical company, acquired Vigene Biosciences Inc., a US-based biotech company, to enhance gene therapy capabilities and establish an end-to-end gene therapy solution in the US. This strategic approach is aimed at fostering long-term revenue and earnings growth potential.
Major companies in the cell therapy market are opting for strategic partnerships to deliver innovative and effective therapies. Genentech Inc., a US biotechnology corporation, partnered with Arsenal Biosciences, Inc., a US-based programmable cell therapy company, in September 2022. The collaboration aims to expedite the development of next-generation cell therapy products, particularly for solid tumors, potentially revolutionizing cancer treatment. This commitment to innovation and collaboration reflects a shared goal of advancing new and effective treatments for cancer patients.
In October 2021, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, acquired GammaDelta Therapeutics Limited for $100 million. This acquisition enabled Takeda to gain access to early-stage cell therapy programs and GammaDelta's allogeneic variable delta 1 (V1) gamma-delta T cell therapy platforms, encompassing both blood-derived and tissue-derived platforms. GammaDelta Therapeutics Limited, based in the UK, specializes in researching and developing T-cell therapy and immunotherapy for cancer treatment.
Major companies operating in the cell therapy market report are Celgene Corporation, JCR Pharmaceuticals Co. Ltd., Baxter Healthcare Corporation, Nipro Corporation, Stempeutics Research Pvt. Ltd., Osiris Therapeutics Inc., Vericel Corporation, AlloSource, Anterogen Co. Ltd., Arteriocyte Medical Systems Inc., MediPost Co. Ltd., Pharmicell Co. Ltd., Corestem Inc., Stemedica Cell Technologies Inc., Adaptimmune Therapeutics PLC, Mesoblast Ltd., Cell Medica Ltd., Cellerant Therapeutics Inc., Kolon TissueGene Inc., Tego Science Inc., Athersys Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Forticell Bioscience Inc., Bone Therapeutics, Holostem Terapie Avanzate S.r.l, Fibrocell Science Inc., AlloCure Inc., TiGenix NV, Cells for Cells, AVROBIO Inc., Cellular Biomedicine Group Inc., Thermo Fisher Scientific Inc., Merck Co. & KGaA, Charles River Laboratories International Inc., Lonza Group Ltd., Catalent Inc. North America was the largest region in the cell therapy market in 2023. The regions covered in the cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The primary techniques employed in cell therapy include stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell treatment, also recognized as regenerative medicine, utilizes stem cells or their derivatives to stimulate the healing response in diseased, defective, or injured tissues. Allogeneic therapies and autologous therapies are the two main types of therapies used in various applications such as oncology, cardiovascular disease (CVD), orthopedics, wound healing, and more.
The cell therapy market research report is one of a series of new reports that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cell Therapy Market Characteristics3. Cell Therapy Market Trends and Strategies32. Global Cell Therapy Market Competitive Benchmarking33. Global Cell Therapy Market Competitive Dashboard34. Key Mergers and Acquisitions in the Cell Therapy Market
4. Cell Therapy Market - Macro Economic Scenario
5. Global Cell Therapy Market Size and Growth
6. Cell Therapy Market Segmentation
7. Cell Therapy Market Regional and Country Analysis
8. Asia-Pacific Cell Therapy Market
9. China Cell Therapy Market
10. India Cell Therapy Market
11. Japan Cell Therapy Market
12. Australia Cell Therapy Market
13. Indonesia Cell Therapy Market
14. South Korea Cell Therapy Market
15. Western Europe Cell Therapy Market
16. UK Cell Therapy Market
17. Germany Cell Therapy Market
18. France Cell Therapy Market
19. Italy Cell Therapy Market
20. Spain Cell Therapy Market
21. Eastern Europe Cell Therapy Market
22. Russia Cell Therapy Market
23. North America Cell Therapy Market
24. USA Cell Therapy Market
25. Canada Cell Therapy Market
26. South America Cell Therapy Market
27. Brazil Cell Therapy Market
28. Middle East Cell Therapy Market
29. Africa Cell Therapy Market
30. Cell Therapy Market Competitive Landscape and Company Profiles
31. Cell Therapy Market Other Major and Innovative Companies
35. Cell Therapy Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Cell Therapy Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cell therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Technique: Stem Cell Therapy; Cell Vaccine; Adoptive Cell Transfer (ACT); Fibroblast Cell Therapy; Chondrocyte Cell Therapy
2) By Therapy Type: Allogeneic Therapies; Autologous Therapies
3) By Application: Oncology; Cardiovascular Disease (CVD); Orthopedic; Wound Healing; Other Applications
Key Companies Mentioned: Celgene Corporation; JCR Pharmaceuticals Co. Ltd.; Baxter Healthcare Corporation; Nipro Corp.; Stempeutics Research Pvt. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Celgene Corporation
- JCR Pharmaceuticals Co. Ltd.
- Baxter Healthcare Corporation
- Nipro Corp.
- Stempeutics Research Pvt. Ltd.
- Osiris Therapeutics Inc.
- Vericel Corporation
- AlloSource
- Anterogen Co. Ltd.
- Arteriocyte Medical Systems Inc.
- MediPost Co. Ltd.
- Pharmicell Co. Ltd.
- Corestem Inc.
- Stemedica Cell Technologies Inc.
- Adaptimmune Therapeutics plc
- Mesoblast Ltd.
- Cell Medica Ltd.
- Cellerant Therapeutics Inc.
- Kolon TissueGene Inc.
- Tego Science Inc.
- Athersys Inc.
- 4D Molecular Therapeutics Inc.
- Abeona Therapeutics Inc.
- Forticell Bioscience Inc.
- Bone Therapeutics
- Holostem Terapie Avanzate S.r.l
- Fibrocell Science Inc.
- AlloCure Inc.
- TiGenix NV
- Cells for Cells
- AVROBIO Inc.
- Cellular Biomedicine Group Inc.
- Thermo Fisher Scientific Inc.
- Merck Co. & KGaA
- Charles River Laboratories International Inc.
- Lonza Group Ltd.
- Catalent Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 14.72 Billion |
| Forecasted Market Value ( USD | $ 25.86 Billion |
| Compound Annual Growth Rate | 15.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 37 |
